# Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

> **NCT02367872** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 48 (actual)

## Conditions studied

- Renal Impairment
- Hepatic Impairment

## Interventions

- **DRUG:** TAK-272

## Key facts

- **NCT ID:** NCT02367872
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02367872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02367872, "Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02367872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*